Warren Greth

1.2k total citations · 1 hit paper
13 papers, 966 citations indexed

About

Warren Greth is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Warren Greth has authored 13 papers receiving a total of 966 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 9 papers in Immunology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Warren Greth's work include Systemic Lupus Erythematosus Research (9 papers), T-cell and B-cell Immunology (6 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Warren Greth is often cited by papers focused on Systemic Lupus Erythematosus Research (9 papers), T-cell and B-cell Immunology (6 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Warren Greth collaborates with scholars based in United States, United Kingdom and Canada. Warren Greth's co-authors include Liangwei Wang, Kenneth Kalunian, Jörn Drappa, Munther A. Khamashta, Richard Furie, Joan T. Merrill, Victoria P. Werth, Gabor G. Illei, Tim Bancroft and Wendy I. White and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and British Journal of Clinical Pharmacology.

In The Last Decade

Warren Greth

12 papers receiving 940 citations

Hit Papers

Sifalimumab, an anti-interferon-α monoclonal antibody, in... 2016 2026 2019 2022 2016 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
    2016 382 citations Munther A. Khamashta, Joan T. Merrill et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Warren Greth United States 12 696 557 231 185 143 13 966
Laura Nuño Spain 16 562 0.8× 478 0.9× 209 0.9× 159 0.9× 56 0.4× 60 944
Yusuke Miyazaki Japan 16 628 0.9× 554 1.0× 102 0.4× 106 0.6× 87 0.6× 60 993
Stefania Sacco Italy 13 502 0.7× 264 0.5× 144 0.6× 155 0.8× 134 0.9× 20 958
Andrea L. Sestak United States 12 631 0.9× 557 1.0× 166 0.7× 86 0.5× 143 1.0× 17 946
K Steinsson Iceland 19 628 0.9× 401 0.7× 180 0.8× 64 0.3× 193 1.3× 35 928
J. Box United States 7 763 1.1× 367 0.7× 204 0.9× 66 0.4× 163 1.1× 10 1.1k
Antonios Psarras United Kingdom 14 378 0.5× 406 0.7× 70 0.3× 80 0.4× 105 0.7× 27 790
Vincent Ruland Germany 15 557 0.8× 391 0.7× 173 0.7× 100 0.5× 220 1.5× 18 833
Beverly S. Franek United States 17 735 1.1× 735 1.3× 132 0.6× 62 0.3× 103 0.7× 25 1.1k
Sandra Lasbleiz France 16 502 0.7× 220 0.4× 138 0.6× 172 0.9× 55 0.4× 35 827

Countries citing papers authored by Warren Greth

Since Specialization
Citations

This map shows the geographic impact of Warren Greth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Warren Greth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Warren Greth more than expected).

Fields of papers citing papers by Warren Greth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Warren Greth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Warren Greth. The network helps show where Warren Greth may publish in the future.

Co-authorship network of co-authors of Warren Greth

This figure shows the co-authorship network connecting the top 25 collaborators of Warren Greth. A scholar is included among the top collaborators of Warren Greth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Warren Greth. Warren Greth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Greth, Warren, Gabriel J. Robbie, Philip Z. Brohawn, Micki Hultquist, & Bing Yao. (2016). Targeting the Interferon Pathway with Sifalimumab for the Treatment of Systemic Lupus Erythematosus. Immunotherapy. 9(1). 57–70. 11 indexed citations
2.
Khamashta, Munther A., Joan T. Merrill, Victoria P. Werth, et al.. (2016). Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases. 75(11). 1909–1916. 382 indexed citations breakdown →
3.
Khamashta, Munther A., et al.. (2015). AB0183 The Effect of Geography on the Efficacy of Sifalimumab, an Anti-Interferon-Alpha Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases. 74. 951–952. 1 indexed citations
4.
Zheng, Bo, Xiang‐Qing Yu, Warren Greth, & Gabriel J. Robbie. (2015). Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients. British Journal of Clinical Pharmacology. 81(5). 918–928. 16 indexed citations
5.
Petri, Michelle, Daniel J. Wallace, Alberto Spindler, et al.. (2013). Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study. Arthritis & Rheumatism. 65(4). 1011–1021. 200 indexed citations
6.
Furst, Daniel E., Ann E. Clarke, Ancilla W. Fernandes, et al.. (2013). Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population. Journal of Medical Economics. 16(4). 500–509. 21 indexed citations
7.
Petri, Michelle, Ariane K. Kawata, Ancilla W. Fernandes, et al.. (2013). Impaired Health Status and the Effect of Pain and Fatigue on Functioning in Clinical Trial Patients with Systemic Lupus Erythematosus. The Journal of Rheumatology. 40(11). 1865–1874. 24 indexed citations
8.
Higgs, Brandon W., Marlon C. Rebelatto, Wenhua Zhu, et al.. (2013). Suppression of soluble T cell-associated proteins by an anti-interferon-  monoclonal antibody in adult patients with dermatomyositis or polymyositis. Lara D. Veeken. 53(4). 686–695. 32 indexed citations
9.
Higgs, Brandon W., Wei Zhu, Chris Morehouse, et al.. (2013). A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Annals of the Rheumatic Diseases. 73(1). 256–262. 131 indexed citations
10.
11.
Furst, Daniel E., Ancilla W. Fernandes, Şerban R. Iorga, Warren Greth, & Tim Bancroft. (2012). Annual Medical Costs and Healthcare Resource Use in Patients with Systemic Sclerosis in an Insured Population. The Journal of Rheumatology. 39(12). 2303–2309. 27 indexed citations
12.
Fürst, Daniel E., Ancilla W. Fernandes, Şerban R. Iorga, Warren Greth, & Tim Bancroft. (2012). Epidemiology of Systemic Sclerosis in a Large US Managed Care Population. The Journal of Rheumatology. 39(4). 784–786. 38 indexed citations
13.
Furst, D.E., et al.. (2012). Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. Lupus. 22(1). 99–105. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Nuño Breakdown of academic impact, for papers by Yusuke Miyazaki Breakdown of academic impact, for papers by Stefania Sacco Breakdown of academic impact, for papers by Andrea L. Sestak Breakdown of academic impact, for papers by K Steinsson Breakdown of academic impact, for papers by J. Box Breakdown of academic impact, for papers by Antonios Psarras Breakdown of academic impact, for papers by Vincent Ruland Breakdown of academic impact, for papers by Beverly S. Franek Breakdown of academic impact, for papers by Sandra Lasbleiz
Rankless by CCL
2026